Terms: = Ovarian cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
376 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. RAF inhibitor re-challenge therapy in braf-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE; Roszik J; Ahmed J; Barretto CMN; Nardo M; Campbell E; Johnson AM; Piha-Paul SA; Oliva ICG; Weathers SP; Cabanillas M; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer; 2024 Mar; 23(1):64. PubMed ID: 38532456
[TBL] [Abstract] [Full Text] [Related]
3. Evaluating the Prognostic Factors and Survival Rates of Endometrial cancer Patients in a Tertiary Referral Hospital in Northeast Thailand.
Wannasin R; Thinkhamrop K; Kelly M; Likitdee N
Asian Pac J Cancer Prev; 2024 Feb; 25(2):671-679. PubMed ID: 38415555
[TBL] [Abstract] [Full Text] [Related]
4. Identification of Germline
Pires C; Saramago A; Moura MM; Li J; Donato S; Marques IJ; Belo H; Machado AC; Cabrera R; Grünewald TGP; Leite V; Cavaco BM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396644
[TBL] [Abstract] [Full Text] [Related]
5. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
6. Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor.
Teng QX; Lei ZN; Wang JQ; Yang Y; Wu ZX; Acharekar ND; Zhang W; Yoganathan S; Pan Y; Wurpel J; Chen ZS; Fang S
Drug Resist Updat; 2024 Mar; 73():101028. PubMed ID: 38340425
[TBL] [Abstract] [Full Text] [Related]
7. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
8. Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
Zhou I; Plana D; Palmer AC
Clin Cancer Res; 2024 Feb; 30(4):786-792. PubMed ID: 38109210
[TBL] [Abstract] [Full Text] [Related]
9. The use of fertility treatments among reproductive-aged women after cancer.
Kipling LM; Shandley LM; Mertens AC; Spencer JB; Howards PP
Fertil Steril; 2024 Apr; 121(4):578-588. PubMed ID: 38103881
[TBL] [Abstract] [Full Text] [Related]
10. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract] [Full Text] [Related]
11. Inherited BRCA1 and RNF43 pathogenic variants in a familial colorectal cancer type X family.
Chan JM; Clendenning M; Joseland S; Georgeson P; Mahmood K; Joo JE; Walker R; Como J; Preston S; Chai SM; Chu YL; Meyers AL; Pope BJ; Duggan D; Fink JL; Macrae FA; Rosty C; Winship IM; Jenkins MA; Buchanan DD
Fam Cancer; 2024 Mar; 23(1):9-21. PubMed ID: 38063999
[TBL] [Abstract] [Full Text] [Related]
12. Vegetarian diets and risk of all-cause mortality in a population-based prospective study in the United States.
Blackie K; Bobe G; Takata Y
J Health Popul Nutr; 2023 Nov; 42(1):130. PubMed ID: 37996932
[TBL] [Abstract] [Full Text] [Related]
13. Mucinous cystadenocarcinoma of the breast harbours TRPS1 expressions and PIK3CA alterations.
Chen WY; Hu YH; Tsai YH; Hang JF; Tan PH; Chen CJ
Histopathology; 2024 Feb; 84(3):550-555. PubMed ID: 37983855
[TBL] [Abstract] [Full Text] [Related]
14. Long term activity of vemurafenib in cancers with braf mutations: the ACSE basket study for advanced cancers other than braf
Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
[TBL] [Abstract] [Full Text] [Related]
15. Treatment of Recurrent Low-grade Serous ovarian cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract] [Full Text] [Related]
16. Role of gene sequencing in classifying struma ovarii: braf p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
17.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract] [Full Text] [Related]
18. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.
Wilcox N; Dumont M; González-Neira A; Carvalho S; Joly Beauparlant C; Crotti M; Luccarini C; Soucy P; Dubois S; Nuñez-Torres R; Pita G; Gardner EJ; Dennis J; Alonso MR; Álvarez N; Baynes C; Collin-Deschesnes AC; Desjardins S; Becher H; Behrens S; Bolla MK; Castelao JE; Chang-Claude J; Cornelissen S; Dörk T; Engel C; Gago-Dominguez M; Guénel P; Hadjisavvas A; Hahnen E; Hartman M; Herráez B; ; Jung A; Keeman R; Kiechle M; Li J; Loizidou MA; Lush M; Michailidou K; Panayiotidis MI; Sim X; Teo SH; Tyrer JP; van der Kolk LE; Wahlström C; Wang Q; Perry JRB; Benitez J; Schmidt MK; Schmutzler RK; Pharoah PDP; Droit A; Dunning AM; Kvist A; Devilee P; Easton DF; Simard J
Nat Genet; 2023 Sep; 55(9):1435-1439. PubMed ID: 37592023
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma.
Gorczyński A; Miszewski K; Gager Y; Koch S; Pötschke J; Ugrinovski D; Gabert J; Pospieszyńska A; Wydra D; Duchnowska R; Szymanowski B; Cierniak S; Kruecken I; Neumann K; Mirkov K; Biernat W; Czapiewski P
Cancer Biomark; 2023; 38(1):17-26. PubMed ID: 37522200
[TBL] [Abstract] [Full Text] [Related]
20. Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous ovarian Carcinoma.
Shibahara M; Kurita T; Murakami M; Harada H; Koi C; Izumi H; Yoshino K
Anticancer Res; 2023 Aug; 43(8):3787-3792. PubMed ID: 37500176
[TBL] [Abstract] [Full Text] [Related]
[Next]
